SEHK:1877Biotechs
Junshi Biosciences (SEHK:1877) Losses Worsen Despite 23.7% Revenue Growth, Challenging Bullish Narratives
Shanghai Junshi Biosciences (SEHK:1877) remains unprofitable, with annual losses worsening by an average of 2.7% over the past five years, and net profit margins showing no signs of improvement. Despite this, analysts expect revenue to grow at a robust 23.7% per year, significantly outpacing the 8.6% growth forecast for the broader Hong Kong market. With the company expected to stay in the red for at least three more years, investors are weighing the attraction of high sales growth against...